Denali Therapeutics Inc. DNLI
$22.29
▲ +3.04% 24H
About
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutics to address neurodegenerative and lysosomal storage diseases. The company engineers product candidates using proprietary technologies such as Antibody Transport Vehicle (ATV) and Enzyme Transport Vehicle (ETV) to e…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees507
TickerDNLI
Statistics
Market Cap$3.54B
Revenue (TTM)$0
Net Income-$512.5M
Net Margin—
EPS$-2.97
P/E-7.07
P/S—
P/B3.60
EV/EBITDA-4.37
ROE-49.6%
Dividend Yield—
Price$22.29
Data: Twelve Data · Revenue = mcap / P/S